Membrane permeabilization by Islet Amyloid Polypeptide

Chemistry and Physics of Lipids

Volumn 160, Issue 1, 2009, Pages 1-10

  Engel, Maarten F M ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

cell death; Amylin; Amyloid fibril; Misfolding disease; Phospholipid bilayer integrity; Type 2 diabetes mellitus

Indexed keywords

AMYLIN;

AMINO ACID SEQUENCE; CELL DEATH; CYTOTOXICITY; FIBER; MEMBRANE PERMEABILITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW;

AMINO ACID SEQUENCE; AMYLOID; CELL MEMBRANE PERMEABILITY; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN-SECRETING CELLS; LIPID BILAYERS; MOLECULAR SEQUENCE DATA;

EID: 67349142581     PISSN: 00093084     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chemphyslip.2009.03.008     Document Type: Review

References (117)

1. Abedini A., and Raleigh D.P. The role of His-18 in amyloid formation by human islet amyloid polypeptide. Biochemistry 44 (2005) 16284-16291
2. Aisenbrey C., Borowik T., Byström R., Bokvist M., Lindström F., Misiak H., Sani M.-A., and Gröbner G. How is protein aggregation in amyloidogenic diseases modulated by biological membranes?. Eur. Biophys. J. 37 (2008) 247-255
3. Anguiano M., Nowak R.J., and Lansbury Jr. P.T. Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes. Biochemistry 41 (2002) 11338-11343
4. Apostolidou M., Jayasinghe S.A., and Langen R. Structure of α-helical membrane-bound hIAPP and its implications for membrane-mediated misfolding. J. Biol. Chem. 283 (2008) 17205-17210
5. Arispe N., Rojas E., and Pollard H.B. Alzheimer disease amyloid β protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 567-571
6. Bhogal R., Smith D.M., Purkiss P., and Bloom S.R. Molecular identification of binding sites for calcitonin gene-related peptide (CGRP) and islet amyloid polypeptide (IAPP) in mammalian lung: species variation and binding of truncated CGRP and IAPP. Endocrinology 133 (1993) 2351-2361
7. Brender J.R., Hartman K., Reid K.R., Kennedy R.T., and Ramamoorthy A. A single mutation in the nonamyloidogenic region of Islet Amyloid Polypeptide greatly reduces toxicity. Biochemistry 47 (2008) 12680-12688
8. Brender J.R., Lee E.L., Cavitt M.A., Gafni A., Steel D.G., and Ramamoorthy A. Amyloid fiber formation and membrane disruption are separate processes localized in two distinct regions of IAPP, the type-2-diabetes-related peptide. J. Am. Chem. Soc. 130 (2008) 6424-6429
9. Carulla N., Caddy G.L., Hall D.R., Zurdo J., Gairi M., Feliz M., Giralt E., Robinson C.V., and Dobson C.M. Molecular recycling within amyloid fibrils. Nature 436 (2005) 554-558
10. Casas S., Novials A., Reimann F., Gomis R., and Gribble F. Calcium elevation in mouse pancreatic beta cells evoked by extracellular human islet amyloid polypeptide involves activation of the mechanosensitive ion channel TRPV4. Diabetologia 51 (2008) 2252-2262
11. Chiti F., and Dobson C.M. Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 75 (2006) 333-366
12. Clark A., Lewis C.E., Willis A.C., Cooper G.J.S., Morris J.F., Reid K.B.M., and Turner R.C. Islet amyloid formed from diabetes-associated peptide may be pathogenic in type-2 diabetes. Lancet 330 (1987) 231-234
13. Cobb J.E., Kassel D.B., Sugg E.E., Burkhart W., Geddie N., Steele A., and Anderegg R.J. Mercury in a commercial preparation of rat amylin. Pept. Res. 5 (1992) 161-164
14. Collins S.R., Douglass A., Vale R.D., and Weissman J.S. Mechanism of prion propagation: amyloid growth occurs by monomer addition. PLoS Biol. 2 (2004) 1582-1590
15. Cooper G.J., Willis A.C., Clark A., Turner R.C., Sim R.B., and Reid K.B. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc. Natl. Acad. Sci. U.S.A. 84 (1987) 8628-8632
16. de Koning E.J.P., Morris E.R., Hofhuis F.M.A., Posthuma G., Höppener J.W.M., Morris J.F., Capel P.J.A., Clark A., and Verbeek J.S. Intracellular and extracellular amyloid fibrils are formed in cultured pancreatic-islets of transgenic mice expressing human islet amyloid polypeptide. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 8467-8471
17. Demuro A., Mina E., Kayed R., Milton S.C., Parker I., and Glabe C.G. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J. Biol. Chem. 280 (2005) 17294-17300
18. Domanov Y.A., and Kinnunen P.K. Islet amyloid polypeptide forms rigid lipid-protein amyloid fibrils on supported phospholipid bilayers. J. Mol. Biol. 376 (2008) 42-54
19. Engel M.F.M., Khemtémourian L., Kleijer C.C., Meeldijk H.J.D., Jacobs J., Verkleij A.J., de Kruijff B., Killian J.A., and Höppener J.W.M. Membrane damage by human islet amyloid polypeptide through fibril growth at the membrane. Proc. Natl. Acad. Sci. U.S.A. 105 (2008) 6033-6038
20. Engel M.F.M., Visser A.J.W.G., and van Mierlo C.P.M. Conformation and orientation of a protein folding intermediate trapped by adsorption. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 11316-11321
21. Engel M.F.M., Yigittop H., Elgersma R.C., Rijkers D.T.S., Liskamp R.M.J., de Kruijff B., Höppener J.W.M., and Killian J.A. Islet amyloid polypeptide inserts into phospholipid monolayers as monomer. J. Mol. Biol. 356 (2006) 783-789
22. Friedman R., Pellarin R., and Caflisch A. Amyloid aggregation on lipid bilayers and its impact on membrane permeability. J. Mol. Biol. 387 (2009) 407-415
23. Gellermann G.P., Appel T.R., Davies P., and Diekmann S. Paired helical filaments contain small amounts of cholesterol, phosphatidylcholine and sphingolipids. Biol. Chem. 387 (2006) 1267-1274
24. Gellermann G.P., Appel T.R., Tannert A., Radestock A., Hortschansky P., Schroeckh V., Leisner C., Lütkepohl T., Shtrasburg S., Röcken C., Pras M., Linke R.P., Diekmann S., and Fändrich M. Raft lipids as common components of human extracellular amyloid fibrils. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 6297-6302
25. Gharibyan A.L., Zamotin V., Yanamandra K., Moskaleva O.S., Margulis B.A., Kostanyan I.A., and Morozova-Roche L.A. Lysozyme amyloid oligomers and fibrils induce cellular death via different apoptotic/necrotic pathways. J. Mol. Biol. 365 (2006) 1337-1349
26. Giacomelli C.E., and Norde W. Conformational changes of the amyloid β-peptide (1-40) adsorbed on solid surfaces. Macromol. Biosci. 5 (2005) 401-407
27. Gilead S., and Gazit E. The role of the 14-20 domain of the islet amyloid polypeptide in amyloid formation. Exp. Diabetes Res. 2008 (2008) 256954
28. Gilead S., Wolfenson H., and Gazit E. Molecular mapping of the recognition interface between the Islet Amyloid Polypeptide and Insulin. Angew. Chem. Int. Ed. 45 (2006) 6476-6480
29. Glabe C.G. Conformation-dependent antibodies target diseases of protein misfolding. Trends Biochem. Sci. 29 (2004) 542-547
30. Glabe C.G. Structural classification of toxic amyloid oligomers. J. Biol. Chem. 283 (2008) 29639-29643
31. Glabe C.G., and Kayed R. Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. Neurology 66 (2006) S74-S78
32. Goldsbury C., Goldie K., Pellaud J., Seelig J., Frey P., Müller S.A., Kistler J., Cooper G.J.S., and Aebi U. Amyloid fibril formation from full-length and fragments of amylin. J. Struct. Biol. 130 (2000) 352-362
33. Goldsbury C.S., Cooper G.J., Goldie K.N., Muller S.A., Saafi E.L., Gruijters W.T., Misur M.P., Engel A., Aebi U., and Kistler J. Polymorphic fibrillar assembly of human amylin. J. Struct. Biol. 119 (1997) 17-27
34. Golpon H.A., Puchner A., Schmidt L., Jungclas H., Barth P., Welte T., Wichert P.V., and Feddersen C.O. Mercury contamination of rat amylin mimics vasoactivity and cytotoxic effects. Peptides 24 (2003) 1157-1162
35. Gonzalez M.R., Bischofberger M., Pernot L., van der Goot F.G., and Freche B. Bacterial pore-forming toxins: the (w)hole story?. Cell Mol. Life Sci. 65 (2008) 493-507
36. Gorbenko G.P., and Kinnunen P.K.J. The role of lipid-protein interactions in amyloid-type protein fibril formation. Chem. Phys. Lipids 141 (2006) 72-82
37. Green J.D., Goldsbury C., Kistler J., Cooper G.J.S., and Aebi U. Human amylin oligomer growth and fibril elongation define two distinct phases in amyloid formation. J. Biol. Chem. 279 (2004) 12206-12212
38. Green J.D., Kreplak L., Goldsbury C., Li Blatter X., Stolz M., Cooper G.S., Seelig A., Kistler J., and Aebi U. Atomic force microscopy reveals defects within mica supported lipid bilayers induced by the amyloidogenic human amylin peptide. J. Mol. Biol. 342 (2004) 877-887
39. Griffin M.D.W., Mok M.L.Y., Wilson L.M., Pham C.L.L., Waddington L.J., Perugini M.A., and Howlett G.J. Phospholipid interaction induces molecular level polymorphism in apolipoprotein C-II amyloid fibrils via alternative assembly pathways. J. Mol. Biol. 375 (2008) 240-256
40. Haataja L., Gurlo T., Huang C.J., and Butler P.C. Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis. Endocr. Rev. 29 (2008) 303-316
41. Hay D.L., Christopoulos G., Christopoulos A., and Sexton P.M. Amylin receptors: molecular composition and pharmacology. Biochem. Soc. Trans. 32 (2004) 865-867
42. Higham C.E., Jaikaran E.T.A.S., Fraser P.E., Gross M., and Clark A. Preparation of synthetic human islet amyloid polypeptide (IAPP) in a stable conformation to enable study of conversion to amyloid-like fibrils. FEBS Lett. 470 (2000) 55-60
43. Höppener J.W.M., Ahrén B., and Lips C.J.M. Islet amyloid and type 2 diabetes mellitus. N. Engl. J. Med. 343 (2000) 411-419
44. Jaikaran E., Higham C.E., Serpell L.C., Zurdo J., Gross M., Clark A., and Fraser P.E. Identification of a novel human islet amyloid polypeptide β-sheet domain and factors influencing fibrillogenesis. J. Mol. Biol. 308 (2001) 515-525
45. Jaikaran E.T., and Clark A. Islet amyloid and type 2 diabetes: from molecular misfolding to islet pathophysiology. Biochim. Biophys. Acta 1537 (2001) 179-203
46. Janson J., Ashley R.H., Harrison D., McIntyre S., and Butler P.C. The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 48 (1999) 491-498
47. Jayasinghe S.A., and Langen R. Identifying structural features of fibrillar islet amyloid polypeptide using site-directed spin labeling. J. Biol. Chem. 279 (2004) 48420-48425
48. Jayasinghe S.A., and Langen R. Lipid membranes modulate the structure of islet amyloid polypeptide. Biochemistry 44 (2005) 12113-12119
49. Kagan B.L. Amyloidosis and protein folding. Science 307 (2005) 42-43
50. Kagan B.L., Azimov R., and Azimova R. Amyloid peptide channels. J. Membr. Biol. 202 (2004) 1-10
51. Kajava A.V., Aebi U., and Steven A.C. The parallel superpleated beta-structure as a model for amyloid fibrils of human amylin. J. Mol. Biol. 348 (2005) 247-252
52. Karlsson E. IAPP as a regulator of glucose homeostasis and pancreatic hormone secretion (review). Int. J. Mol. Med. 3 (1999) 577-584
53. Kawahara M., Kuroda Y., Arispe N., and Rojas E. Alzheimer's β-amyloid, human islet amylin, and prion protein fragment evoke intracellular free calcium elevations by a common mechanism in a hypothalamic GnRH neuronal cell line. J. Biol. Chem. 275 (2000) 14077-14083
54. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., and Glabe C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300 (2003) 486-489
55. Kayed R., Pensalfini A., Margol L., Sokolov Y., Sarsoza F., Head E., Hall J., and Glabe C. Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer. J. Biol. Chem. 284 (2009) 4230-4237
56. Kayed R., Sokolov Y., Edmonds B., McIntire T.M., Milton S.C., Hall J.E., and Glabe C.G. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J. Biol. Chem. 279 (2004) 46363-46366
57. Knight J.D., Hebda J.A., and Miranker A.D. Conserved and cooperative assembly of membrane-bound α-helical states of islet amyloid polypeptide. Biochemistry 45 (2006) 9496-9508
58. Knight J.D., and Miranker A.D. Phospholipid catalysis of diabetic amyloid assembly. J. Mol. Biol. 341 (2004) 1175-1187
59. Knight J.D., Williamson J.A., and Miranker A.D. Interaction of membrane-bound islet amyloid polypeptide with soluble and crystalline insulin. Protein Sci. 17 (2008) 1850-1856
60. Koffie R.M., Meyer-Luehmann M., Hashimoto T., Adams K.W., Mielke M.L., Garcia-Alloza M., Micheva K.D., Smith S.J., Kim M.L., Lee V.M., Hyman B.T., and Spires-Jones T.L. Oligomeric amyloid β associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc. Natl. Acad. Sci. U.S.A. 106 (2009) 4012-4017
61. Konarkowska B., Aitken J.F., Kistler J., Zhang S., and Cooper G.J.S. The aggregation potential of human amylin determines its cytotoxicity towards islet β-cells. FEBS J. 273 (2006) 3614-3624
62. Konno T., Oiki S., and Morii T. Synergistic action of polyanionic and non-polar cofactors in fibrillation of human islet amyloid polypeptide. FEBS Lett. 581 (2007) 1635-1638
63. Kostka M., Hogen T., Danzer K.M., Levin J., Habeck M., Wirth A., Wagner R., Glabe C.G., Finger S., Heinzelmann U., Garidel P., Duan W., Ross C.A., Kretzschmar H., and Giese A. Single-particle characterization of iron-induced pore-forming α-synuclein oligomers. J. Biol. Chem. 283 (2008) 10992-11003
64. Kourie J.I., Culverson A.L., Farrelly P.V., Henry C.L., and Laohachai K.N. Heterogeneous amyloid-formed ion channels as a common cytotoxic mechanism: implications for therapeutic strategies against amyloidosis. Cell Biochem. Biophys. 36 (2002) 191-207
65. Lashuel H.A., Hartley D., Petre B.M., Walz T., and Lansbury P.T. Neurodegenerative disease-amyloid pores from pathogenic mutations. Nature 418 (2002) 291-1291
66. Lashuel H.A., and Lansbury P.T. Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins?. Q. Rev. Biophys. 39 (2006) 167-201
67. Lin C.-Y., Gurlo T., Kayed R., Butler A.E., Haataja L., Glabe C.G., and Butler P.C. Toxic human islet amyloid polypeptide (h-IAPP) oligomers are intracellular, and vaccination to induce anti-toxic oligomer antibodies does not prevent h-IAPP-induced β-cell apoptosis in h-IAPP transgenic mice. Diabetes 56 (2007) 1324-1332
68. Linse S., Cabaleiro-Lago C., Xue W.F., Lynch I., Lindman S., Thulin E., Radford S.E., and Dawson K.A. Nucleation of protein fibrillation by nanoparticles. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 8691-8696
69. Lopes D.H.J., Meister A., Gohlke A., Hauser A., Blume A., and Winter R. Mechanism of IAPP fibrillation at lipid interfaces studied by infrared reflection absorption spectroscopy (IRRAS). Biophys. J. 93 (2007) 3132-3141
70. Lorenzo A., Razzaboni B., Weir G.C., and Yankner B.A. Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature 368 (1994) 756-760
71. Luca S., Yau W.M., Leapman R., and Tycko R. Peptide conformation and supramolecular organization in amylin fibrils: constraints from solid-state NMR. Biochemistry 46 (2007) 13505-13522
72. Madine J., Jack E., Stockley P.G., Radford S.E., Serpell L.C., and Middleton D.A. Structural insights into the polymorphism of amyloid-like fibrils formed by region 20-29 of amylin revealed by solid-state NMR and X-ray fiber diffraction. J. Am. Chem. Soc. 130 (2008) 14990-15001
73. Martins I.C., Kuperstein I., Wilkinson H., Maes E., Vanbrabant M., Jonckheere W., Van Gelder P., Hartmann D., D'Hooge R., De Strooper B., Schymkowitz J., and Rousseau F. Lipids revert inert Aβ amyloid fibrils to neurotoxic protofibrils that affect learning in mice. EMBO J. 27 (2008) 224-233
74. Mascioni A., Porcelli F., Ilangovan U., Ramamoorthy A., and Venglia G. Conformational preferences of the amylin nucleation site in SDS micelles: an NMR study. Biopolymers 69 (2003) 29-41
75. Meier J.J., Kayed R., Lin C.-Y., Gurlo T., Haataja L., Jayasinghe S., Langen R., Glabe C.G., and Butler P.C. Inhibition of hIAPP fibril formation does not prevent β-cell death: evidence for distinct actions of oligomers and fibrils of hIAPP. Am. J. Physiol. Endocrinol. Metab. 291 (2006) E1317-E1324
76. Meng F., Marek P., Potter K.J., Verchere C.B., and Raleigh D.P. Rifampicin does not prevent amyloid fibril formation by human islet amyloid polypeptide but does inhibit fibril thioflavin-T interactions: implications for mechanistic studies of β-cell death. Biochemistry 47 (2008) 6016-6024
77. Mirzabekov T.A., Lin M.C., and Kagan B.L. Pore formation by the cytotoxic islet amyloid peptide amylin. J. Biol. Chem. 271 (1996) 1988-1992
78. Mukhopadhyay S., Krishnan R., Lemke E.A., Lindquist S., and Deniz A.A. A natively unfolded yeast prion monomer adopts an ensemble of collapsed and rapidly fluctuating structures. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 2649-2654
79. 1-19 in micelles by NMR spectroscopy. Biochemistry 47 (2008) 12689-12697
80. Nilsson M.R., and Raleigh D.P. Analysis of amylin cleavage products provides new insights into the amyloidogenic region of human amylin. J. Mol. Biol. 294 (1999) 1375-1385
81. Nishi M., Chan S.J., Nagamatsu S., Bell G.I., and Steiner D.F. Conservation of the sequence of islet amyloid polypeptide in five mammals is consistent with its putative role as an islet hormone. Proc. Natl. Acad. Sci. U.S.A. 86 (1989) 5738-5742
82. Norde W., and Lyklema J. Why proteins prefer interfaces. J. Biomater. Sci. Polym. Ed. 2 (1991) 183-202
83. Novitskaya V., Bocharova O.V., Bronstein I., and Baskakov I.V. Amyloid fibrils of mammalian prion protein are highly toxic to cultured cells and primary neurons. J. Biol. Chem. 281 (2006) 13828-13836
84. Okada T., Wakabayashi M., Ikeda K., and Matsuzaki K. Formation of toxic fibrils of Alzheimer's amyloid β-protein-(1-40) by monosialoganglioside GM1, a neuronal membrane component. J. Mol. Biol. 371 (2007) 481-489
85. Orte A., Birkett N.R., Clarke R.W., Devlin G.L., Dobson C.M., and Klenerman D. Direct characterization of amyloidogenic oligomers by single-molecule fluorescence. Proc. Natl. Acad. Sci. U.S.A. 105 (2008) 14424-14429
86. Padrick S.B., and Miranker A.D. Islet amyloid: phase partitioning and secondary nucleation are central to the mechanism of fibrillogenesis. Biochemistry 41 (2002) 4694-4703
87. 2+ increase in primary neuronal cells. J. Biol. Chem. 283 (2008) 29950-29960
88. Pieri L., Bucciantini M., Nosi D., Formigli L., Savistchenko J., Melki R., and Stefani M. The yeast prion Ure2p native-like assemblies are toxic to mammalian cells regardless of their aggregation state. J. Biol. Chem. 281 (2006) 15337-15344
89. Porat Y., Kolusheva S., Jelinek R., and Gazit E. The human islet amyloid polypeptide forms transient membrane-active prefibrillar assemblies. Biochemistry 42 (2003) 10971-10977
90. Quist A., Doudevski I., Lin H., Azimova R., Ng D., Frangione B., Kagan B., Ghiso J., and Lal R. Amyloid ion channels: a common structural link for protein-misfolding disease. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 10427-10432
91. Radovan D., Smirnovas V., and Winter R. Effect of pressure on islet amyloid polypeptide aggregation: revealing the polymorphic nature of the fibrillation process. Biochemistry 47 (2008) 6352-6360
92. Relini A., Cavalleri O., Rolandi R., and Gliozzi A. The two-fold aspect of the interplay of amyloidogenic proteins with lipid membranes. Chem. Phys. Lipids 158 (2009) 1-9
93. Ren P.H., Lauckner J.E., Kachirskaia I., Heuser J.E., Melki R., and Kopito R.R. Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates. Nat. Cell Biol. 11 (2009) 219-225
94. Riddle M.C., and Drucker D.J. Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. Diabetes Care 29 (2006) 435-449
95. Ruschak A.M., and Miranker A.D. Fiber-dependent amyloid formation as catalysis of an existing reaction pathway. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 12341-12346
96. Saafi E.L., Konarkowska B., Zhang S., Kistler J., and Cooper G.J.S. Ultrastructural evidence that apoptosis is the mechanism by which human amylin evokes death in RINm5F pancreatic islet β-cells. Cell Biol. Int. 25 (2001) 339-350
97. Sciacca M.F.M., Pappalardo M., Milardi D., Grasso D.M., and Rosa C.L. Calcium-activated membrane interaction of the islet amyloid polypeptide: implications in the pathogenesis of type II diabetes mellitus. Arch. Biochem. Biophys. 477 (2008) 291-298
98. Scrocchi L.A., Ha K., Chen Y., Wu L., Wang F., and Fraser P.E. Identification of minimal peptide sequences in the (8-20) domain of human islet amyloid polypeptide involved in fibrillogenesis. J. Struct. Biol. 141 (2003) 218-227
99. Shai Y. Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by α-helical antimicrobial and cell non-selective membrane-lytic peptides. Biochim. Biophys. Acta 1462 (1999) 55-70
100. Smith J.F., Knowles T.P., Dobson C.M., Macphee C.E., and Welland M.E. Characterization of the nanoscale properties of individual amyloid fibrils. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 15806-15811
101. Sparr E., Engel M.F.M., Sakharov D.V., Sprong M., Jacobs J., de Kruijff B., Höppener J.W.M., and Killian J.A. Islet amyloid polypeptide-induced membrane leakage involves uptake of lipids by forming amyloid fibers. FEBS Lett. 577 (2004) 117-120
102. Stefani M. Generic cell dysfunction in neurodegenerative disorders: role of surfaces in early protein misfolding, aggregation, and aggregate cytotoxicity. Neuroscientist 13 (2007) 519-531
103. Sumner Makin O., and Serpell L.C. Structural characterisation of islet amyloid polypeptide fibrils. J. Mol. Biol. 335 (2004) 1279-1288
104. Vaiana S.M., Ghirlando R., Yau W.-M., Eaton W.A., and Hofrichter J. Sedimentation studies on human amylin fail to detect low molecular weight oligomers. Biophys. J. 94 (2008) 45-47
105. Wei L., Jiang P., Yau Y.H., Summer H., Shochat S.G., Mu Y., and Pervushin K. Residual structure in islet amyloid polypeptide mediates its interactions with soluble insulin. Biochemistry 48 (2009) 2368-2376
106. Westermark P. Fine structure of islets of Langerhans in insular amyloidosis. Virchows Arch. A Pathol. Pathol. Anat. 359 (1973) 1-18
107. Westermark P., Engström U., Johnson K.H., Westermark G.T., and Betsholtz C. Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 5036-5040
108. Westermark P., Li Z.C., Westermark G.T., Leckström A., and Steiner D.F. Effects of beta cell granule components on human islet amyloid polypeptide fibril formation. FEBS Lett. 379 (1996) 203-206
109. Westermark P., Wernstedt C., Wilander E., Hayden D.W., O'Brien T.D., and Johnson K.H. Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc. Natl. Acad. Sci. U.S.A. 84 (1987) 3881-3885
110. Williamson J.A., and Miranker A.D. Direct detection of transient α-helical states in islet amyloid polypeptide. Protein Sci. 16 (2007) 110-117
111. Wiltzius J.J.W., Sievers S.A., Sawaya M.R., Cascio D., Popov D., Riekel C., and Eisenberg D. Atomic structure of the cross-β spine of Islet Amyloid Polypeptide (Amylin). Protein Sci. 17 (2008) 1467-1474
112. Wogulis M., Wright S., Cunningham D., Chilcote T., Powell K., and Rydel R.E. Nucleation-dependent polymerization is an essential component of amyloid-mediated neuronal cell death. J. Neurosci. 25 (2005) 1071-1080
113. Yip C.M., and McLaurin J. Amyloid-β peptide assembly: a critical step in fibrillogenesis and membrane disruption. Biophys. J. 80 (2001) 1359-1371
114. Yonemoto I.T., Kroon G.J.A., Dyson H.J., Balch W.E., and Kelly J.W. Amylin proprotein processing generates progressively more amyloidogenic peptides that initially sample the helical state. Biochemistry 47 (2008) 9900-9910
115. Zhang L., Zhong J., Huang L., Wang L., Hong Y., and Sha Y. Parallel-oriented fibrogenesis of a β-sheet forming peptide on supported lipid bilayers. J. Phys. Chem. B 112 (2008) 8950-8954
116. Zhang S., Liu J., Dragunow M., and Cooper G.J. Fibrillogenic amylin evokes islet β-cell apoptosis through linked activation of a caspase cascade and JNK1. J. Biol. Chem. 278 (2003) 52810-52819
117. Zhao H., Tuominen E.K.J., and Kinnunen P.K.J. Formation of amyloid fibers triggered by phosphatidylserine-containing membranes. Biochemistry 43 (2004) 10302-10307